Sarepta Therapeutics Sees Unusually High Options Volume (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders acquired 4,867 call options on the company. This represents an increase of approximately 60% compared to the typical volume of 3,049 call options.

Sarepta Therapeutics Stock Performance

SRPT traded up $1.84 during trading hours on Wednesday, hitting $17.62. 1,292,077 shares of the stock were exchanged, compared to its average volume of 2,894,667. The stock has a 50-day simple moving average of $18.93 and a 200-day simple moving average of $19.69. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $25.32. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -18.11, a price-to-earnings-growth ratio of 0.17 and a beta of 0.21. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62.

Get Sarepta Therapeutics alerts:

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm had revenue of $730.80 million for the quarter, compared to analysts’ expectations of $474.16 million. During the same period last year, the business posted ($3.42) earnings per share. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. Analysts anticipate that Sarepta Therapeutics will post 3.99 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in Sarepta Therapeutics by 454.6% in the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after buying an additional 6,390,860 shares during the last quarter. First Trust Advisors LP lifted its stake in Sarepta Therapeutics by 107.6% in the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after buying an additional 2,143,211 shares during the last quarter. Vanguard Group Inc. lifted its stake in Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock valued at $208,452,000 after buying an additional 1,657,267 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Sarepta Therapeutics by 183.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after buying an additional 1,129,610 shares during the last quarter. Finally, Erste Asset Management GmbH lifted its stake in Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after buying an additional 1,064,530 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on SRPT shares. Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research note on Tuesday, April 7th. Oppenheimer reiterated an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th. Mizuho increased their target price on Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Eight equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $24.77.

Check Out Our Latest Analysis on Sarepta Therapeutics

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.

Featured Articles

• Five stocks we like better than Sarepta Therapeutics
• Draining the Tank: Big Oil Runs on Fumes
• Microsoft’s Xbox Problem Is Bigger Than a Console War
• Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan
• Flying Under the Radar: Lockheed Martin’s $2.8B Stealth Setup

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.